MARKET

RARE

RARE

Ultragenyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

59.96
-0.92
-1.51%
After Hours: 60.98 +1.02 +1.70% 16:53 01/17 EST
OPEN
61.75
PREV CLOSE
60.88
HIGH
61.75
LOW
59.42
VOLUME
736.59K
TURNOVER
--
52 WEEK HIGH
74.50
52 WEEK LOW
35.41
MARKET CAP
3.46B
P/E (TTM)
-8.2922
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of RARE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

RARE News

  • Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $77
  • Benzinga.2d ago
  • The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
  • Benzinga.3d ago
  • The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
  • Benzinga.3d ago
  • GeneTx And Ultragenyx Announce Investigational New Drug Application Is Now Active Active For GTX-102 In Patients with Angelman Syndrome; Enrollment In First Phase 1/2 Study Expected To Begin In 1H 2020
  • Benzinga.4d ago

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About RARE

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.
More

Webull offers Ultragenyx Pharmaceutical Inc (RARE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.